| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | dabrafenib | CTRPv2 | pan-cancer | AAC | -0.046 | 0.4 |
| mRNA | Bortezomib | gCSI | pan-cancer | AAC | 0.067 | 0.4 |
| mRNA | DMOG | GDSC1000 | pan-cancer | AAC | 0.036 | 0.4 |
| mRNA | HG-5-88-01 | GDSC1000 | pan-cancer | AAC | -0.048 | 0.4 |
| mRNA | ruxolitinib | GDSC1000 | pan-cancer | AAC | -0.037 | 0.4 |
| mRNA | AT-406 | CTRPv2 | pan-cancer | AAC | -0.044 | 0.4 |
| mRNA | avrainvillamide | CTRPv2 | pan-cancer | AAC | -0.038 | 0.4 |
| mRNA | Elesclomol | GDSC1000 | pan-cancer | AAC | -0.038 | 0.4 |
| mRNA | FMK | GDSC1000 | pan-cancer | AAC | 0.041 | 0.4 |
| mRNA | RDEA119 | FIMM | pan-cancer | AAC | -0.28 | 0.4 |